INTRODUCTION
The rates of chronic disorders attributed to unbalanced diets and sedentary lifestyles, such as obesity, type 2 diabetes (T2D), and coronary heart disease (CHD), have increased dramatically in recent years, placing an enormous burden on the health and economy of societies worldwide. 1 As a result, the socioeconomic considerations in dietary choices warrant careful assessment for healthcare provisions and for maintaining community resources. A key nutritional strategy to protect against and manage the risk of chronic disease has been to advocate the consumption of dietary oils with healthy fatty acid profiles, such as those rich in monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs), while advising limited consumption of saturated fatty acids (SFAs) and trans fatty acids (TFAs). 2 Vegetable oils are the most common edible oils in the United States and are a significant contributor to daily fat and, thus, caloric intakes. 3 Along with the amount of fat consumed, the quality of dietary fat is a powerful determinant of health. 2 Novel varieties of oils rich in oleic acid (C18:1n-9), which accounts for over 90% of all MUFAs consumed in the United States, 4 including high-oleic canola oil (73% MUFA), high-oleic safflower oil (84% MUFA), and high-oleic algae oil (90% MUFA) (Figure 1) , 5 now have the potential to substantially modify current intakes of dietary fatty acids. Such a shift in intakes at the population level will likely positively impact several biomarkers of health, including circulating lipid profiles, glucose homeostasis, insulin sensitivity, and, to some extent, body composition. 6, 7 In spite of research that links the consumption of MUFA-rich oils to decreased risk factors of disease, data on the health-related economic benefits of increased MUFA intake are limited. The objectives of this research are thus as follows: (1) to assess the health influences of MUFA-rich oil relative to oils rich in other fatty acids using a scoping review approach to the clinical literature; and (2) to utilize the findings of the review to estimate the annual healthcare-and productivityrelated cost savings that would follow reductions in CHD and T2D rates, independently, with increased intake of MUFA-rich oils.
METHODS

Eligibility criteria and data extraction
Using a scoping review approach, comprehensive literature searches were conducted in Scopus, encompassing citations within Embase and MEDLINE, to evaluate the health effects of high-MUFA diets reported from randomized controlled human intervention trials. Scoping reviews are defined by the Canadian Institutes of Health Research as "exploratory projects that systematically map the literature available on a topic, identifying key concepts, theories, sources of evidence and gaps in the research." 8 The search terms "oleic acid," "monounsaturated fatty acid," "monounsaturated fat," and "MUFA" were used to identify peer-reviewed research articles published in English through July 2015. The initial search identified 40 054 articles. After exclusion of animal studies, in vitro studies, and studies in fields not applicable to this research topic, including computer science, mathematics, physics, and astronomy, 11 048 articles remained. The resulting abstracts and full-text articles were then filtered to exclude nonhuman studies, review articles, method articles, non-English articles, and non-health-related source titles. Additional exclusion criteria included studies that had less than a 5% difference in MUFA intake between treatments, interventions lasting for less than 3 weeks, and trials in which results were confounded by weight loss (ie, hypocaloric diets). Finally, studies with dietary intervention arms that by design did not have comparable nutrient intakes, such as those with different total carbohydrate, fiber content, and dietary cholesterol intakes, were also excluded.
The remaining articles (n ¼ 65) 9-73 were reviewed independently (by M.M.H.A. and S.J.) to extract the following data for a cost savings analysis: (1) MUFA intake as a percentage of total energy for each dietary treatment; (2) circulating concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides; (3) body weight and body fat; and (4) circulating concentrations of glucose, insulin, and glycated hemoglobin (HbA1c) along with the homeostatic model assessment. For each of the health biomarkers of interest, the percent changes in endpoints after MUFA-rich vs SFA-rich, MUFA-rich vs TFA-rich, and MUFA-rich vs PUFA-rich treatments were calculated as follows:
Percent magnitude of effect ME ð Þof biomarker ¼ ðMUFA À other fatÞ=other fat Â 100
Then, the percent change in a biomarker per 1% energy from MUFA intake was calculated as:
Percent ME=ðMUFA % energy from high-MUFA treatment -MUFA % energy from other fat treatmentÞ A summary of the findings on the impact of MUFA-rich oil intake on these biomarkers in randomized controlled clinical trials is provided in Table 1 . For the purpose of calculating the percent changes in biomarkers of interest following intakes of MUFA-rich oils compared with other fatty acid-rich oils in different studies, both statistically significant and nonsignificant data were utilized given the inherent variability in constructs, designs, and populations among the studies included in the review (see Table S1 in the Supporting Information online). As well, no assessment of risk of bias or study quality was performed in this work on the basis that descriptions of the included studies suggested generalizability of data pertaining to the impacts of MUFA intake on the biomarkers of interest (see Table  S1 in the Supporting Information online).
Evaluation of cost savings through cost-of-illness analysis
The means and 95% confidence intervals (CIs) of the percent changes in biomarkers of interest per 1% energy from MUFA intake calculated from the included studies, as shown above, were employed in a 4-step cost-of-illness analysis that accomplished the following: (1) estimated the proportion of adults who would potentially purchase and consume MUFA-rich oils at the necessary rate in the United States (success rate); (2) imputed the percent changes in circulating TC and HbA1c concentrations, as traditional risk factors for CHD and T2D, respectively, resulting from the MUFArich oil consumption; (3) predicted the percent reduction in rates of CHD and T2D, separately, that would follow from the reductions in TC and HbA1c concentrations; and (4) calculated the potential annual cost savings associated with the reduced risks of CHD and T2D resulting from the substitution of MUFA-rich oil for other dietary fats. As previously modeled, 74 ,75 a sensitivity analysis of 4 scenarios (universal, optimistic, pessimistic, and very pessimistic) was performed to explore the impact of the uncertainty, resulting in a range of assumptions within each step. This cost savings model was based on the assumption that, over time, increased proportions of men and women residing in the United States, specifically those 18 years and over, 76 would replace half of their current fat intake (daily average of 34% of total dietary energy) 3 with MUFA-rich oils, thus consuming 17% of their daily total energy as MUFA. This level sits within the range of 15% to 20% of moderate MUFA intake recommended by the Academy of Nutrition and Dietetics. 2 Step 1: success rate. Consumer perception of and preference for certain foods is key in determining individual decisions in the marketplace and in dietary behavior at large. Within the context of this cost savings model, the success rate refers to the hypothetical proportions of different US adult populations who would choose to consume MUFA-rich oils over other fats on a daily basis. Although limited information is available on the precise percentages of populations that currently consume MUFA-based diets in the United States, MUFA- rich oils are perceived as favorable dietary components, and consumers are generally receptive to them. For instance, high-oleic oils, including canola oil, safflower oil, and algae oil, have been developed by industry in recent years to replace partially hydrogenated oils in frying and baking applications and as ingredients in salad dressings, margarine, and a variety of other food products. 77 As a result, for example, the domestic consumption of canola oil has increased from 280 million pounds in 1987-1988 to 2797 million pounds in [2008] [2009] . 77 Moreover, in a 2013 survey by researchers from the University of California, Davis, 81% of consumers in the United States viewed olive oil as healthier than other fats. 78 Within this step of the analysis, the "universal scenario" is designed to represent the best-case assumption of potential healthcare and related cost savings if all (ie, 100% of) US adults !18 years were to consume high-MUFA oils. The "optimistic scenario" is an estimate of the potential cost savings that would occur if 50% of adults in the United States consumed high-MUFA oils. The "pessimistic scenario" is an estimate of cost savings that could follow the consumption of high-MUFA oils among 25% of adults in the United States. The "very pessimistic scenario" represents the least-case estimate whereby only 10% of US adults consume the recommended level of MUFA daily.
Step 2: biomarker reduction. The second step of this analysis assessed, separately, the rates of reduction in TC and HbA1c concentrations as established biomarkers of CHD and long-term glycemic control (thus, T2D), respectively, following intakes of MUFA-rich oil. Findings of the literature review were applied. For the TC/CHD module, the literature review identified 60 studies and 76 comparisons of MUFA-rich oil with other oils, revealing an average reduction of À0.46% (95%CI, À0.64% to À0.27%) in serum TC concentrations with each 1% of energy consumed as MUFA. This translates into a TC reduction of À7.8% (95%CI, À10.9% to À4.60%) with intakes of the model's targeted 17% of total daily dietary energy as MUFA. For the HbA1c/T2D module, the literature search identified 3 studies and 4 comparisons of MUFA-rich oil with other oils, revealing an average reduction of À0.16% (95%CI, À0.53% to þ0.21%) in HbA1c concentrations with each 1% of energy consumed as MUFA. With the targeted 17% of total daily dietary energy intake as MUFA, this translates into a À2.7% (95%CI, À9.0% to þ3.60%) HbA1c reduction.
Step 3: reduction in rates of CHD and T2D.
Step 3 of the analysis predicted the percent reduction in CHD and T2D rates, separately, that would follow from the reductions in the TC and HbA1c concentrations with intakes of 17% energy from MUFA (Step 2). Assumptions for this step were extrapolated upon review of prospective observational studies and systematic meta-analyses. The reductions in CHD risk following lower TC concentrations were estimated mainly on the basis of findings in 10 cohorts, 3 international studies in different communities, and 28 randomized controlled trials reviewed by Law et al., 79 who found that each 10% drop in serum TC was associated with an average reduction in CHD of 7% (0% to 14%) in the first 2 years, 22% (15% to 28%) over 2.1 to 5 years, 25% (15% to 35%) after 5 years, and 27% beyond 12 years. Thus, by employing the À7.8% average reduction in TC from Step 2, the CHD reduction due to 17% energy from MUFA intake was estimated at À5.5% (95%CI, À7.6% to À3.2%), À17.2% (95%CI, À23.9% to À10.1%), À19.6% (95%CI, À27.2% to À11.5%), and À21.1% (95%CI, À29.4% to À12.4%), over 0-2 years, 2.1-5 years, 5.1-12 years, and >12 years, respectively.
On the other hand, the reductions in T2D risk following lower HbA1c concentrations were estimated using the observational findings of Stratton et al. 80 In T2D individuals stratified according to updated mean HbA1c concentration categories (with median values) <6% (5.6%), 6% to <7% (6.5%), 7% to <8% (7.5%), 8% to <9% (8.4%), 9% to <10% (9.4%), and >10% (10.6%), each 1% absolute value unit (equivalent to %14%) reduction in HbA1c, following treatment, was associated with a 21% (95%CI, 17% to 24%) decrease in the risk of any endpoint or death related to diabetes over a median of 10 years of follow-up. 80 By employing the À2.7% average reduction in HbA1c from Step 2, the T2D reduction due to 17% energy from MUFA intake was estimated at À2.2% (95%CI, À7.2% to þ2.9%), À2.7% (95%CI, À9.0% to þ3.6%), À3.5% (95%CI, À11.7% to þ4.6%), and À4.1% (95%CI, À13.5% to þ5.4%) over 0-2.5 years, 2.5-5 years, 5-7.5 years, and 7.5-10 years (and beyond), respectively. For the purpose of this model, it was assumed that the relative risk reduction of CHD and T2D per 17% of energy intake from MUFA corresponds to a decrease in the population-wide incidence of these diseases of the same magnitude.
Step 4: cost savings associated with reduced incidence of CHD and T2D. In Step 4, recent estimates of CHD and diabetes costs in the United States were first inflated to their 2015 monetary equivalents and then separately employed within a set of arithmetic calculations involving the success rate, the percent reduction in cost corresponding to each 1% reduction in disease incidence, and the disease reduction resulting from the recommended 17% energy of MUFA intake. This was done to monetize the potential per annum cost savings for the US healthcare system and society in general following reductions in the health conditions of interest occurring after substitution of MUFA-rich oil for other dietary fats. As previously detailed, 81 typically, the costs of diseases are broken down into direct (ie, healthcarerelated) and indirect (ie, productivity-and mortalityrelated) categories. Overviews of recent comprehensive estimates of CHD costs 82 and diabetes costs 83 in the United States, with monetary adjustments based on the US Department of Labor's Consumer Price Index (Medical Care), 84 are summarized in Tables 2 and 3 , respectively. Here, similar to a previously detailed method, 81 components of the direct and indirect categories were examined individually for better assessment of the reduction in costs corresponding to each 1% decrease in the incidence of CHD (Table 4 ) and diabetes (Table 5) . Briefly, short-term hospital cost analyses [85] [86] [87] suggest that 55% to 84% of hospitalization costs, such as salaries and equipment use, are fixed costs and, hence, are not affected by the number of disease cases, whereas 16% to 45% of hospitalization costs, including medications and supplies, vary depending on the number of case admissions. As a result, in the present model, all hospital-related costs were presumed to decrease only by their respective average 0.25% variable cost with each 1% reduction in the incidence of CHD or T2D. On the other hand, the costs of prescribed medicines and home healthcare are, in theory, dependent on disease prevalence. Therefore, such costs were presumed to decline in proportion to the reductions in CHD and T2D incidence, which was also assumed to equally occur with the components of the indirect cost category. Summaries of the assumptions for Steps 1 through 3 of the economic model are provided in Tables 6 and 7 .
RESULTS
In this review, findings of cost savings are based on the analysis of the US population !18 years of age, which was, as of July 2014, approximately 245 270 000 individuals. 76 Four scenarios are covered, corresponding to 10%, 25%, 50%, and 100% of the population who would all migrate from their present pattern of intake to consuming 17% of their daily total dietary energy as MUFAs in place of the same energy level from SFAs, PUFAs, and TFAs combined over short-term (between 0 and 2.5 years), short-to medium-term (up to 5 years), medium-term (5.1-12 or 5-7.5 years), and long-term (>12 or !7.5-10 years) periods. Descriptions of the scenarios are provided below. Proportions of the US population who would consume 17% of their daily total energy as MUFA over short-term (0-2 years; ie, very pessimistic), short-to medium-term (2.1-5 years; ie, pessimistic), medium-term (5.1-12 years; ie, optimistic), and long-term (>12 years; ie, universal) scenarios. b Mean value (95%CI) based on the literature search, where each 1% of energy consumed as MUFA was estimated to result in an average reduction of À0.46% (95%CI, À0.64% to À0.27%) in TC concentrations. c Based on findings of Law et al., 79 where each 10% lower serum TC concentrations was associated with an average reduction in CHD of 7% in the first 2 years, 22% over 5 years, 25% over 12 years, and 27% beyond 12 years. d Mean values (95%CI) based on the calculated reduction in TC due to 17% energy from MUFA intake multiplied by the average CHD reduction due to a 1% reduction in TC concentrations (eg, 7.8 Â 2.5). This reduction only applies to the portion of the population who consume 17% energy as MUFA; ie, in the optimistic scenario, CHD incidence would be reduced by 19.6% in half the population. Proportions of the US population who would consume 17% of their daily total energy as MUFA over short-term (0-2.5 years; ie, very pessimistic), short-to medium-term (2.5-5 years; ie, pessimistic), medium-term (5.0-7.5 years; ie, optimistic), and long-term (7.5 to >10 years; ie, universal) scenarios. b Mean value (95%CI) based on the literature search, where each 1% of energy consumed as MUFA was estimated to result in an average reduction of À0.16% (95%CI, À0.53% to þ0.21%) in HbA1c concentrations. c Based on findings of Stratton et al., 80 where each 1.0% between-treatment difference in absolute values of HbA1c (equivalent to $14% reduction) was associated with an average reduction in any endpoint related to diabetes of 11% at baseline and 21% over a median of 10 years of follow-up. d Mean values (95%CI) based on the calculated reduction in HbA1c due to 17% energy from MUFA intake multiplied by the average T2D reduction due to 1% reduction in HbA1c concentrations (eg, 2.7 Â 1.3). This reduction only applies to the portion of the population who consume 17% energy as MUFA; ie, in the optimistic scenario, T2D incidence would be reduced by 3.5% in half the population. Tables 8 and 9 present the healthcare and productivity cost savings associated with reductions in the CHD and T2D incidences, respectively, following the MUFA consumption. Under the universal scenario, assuming a 100% success rate and a potential benefit over the long term, total annual healthcare and related Values (95%CI) are annual coronary heart disease-related direct and indirect economic savings from the consumption of 17% energy from high-MUFA oil per day. The universal scenario represents the best-case assumption of potential savings if all US adults !18 years were to consume high-MUFA oils over a long term (over 12 years). The optimistic scenario is a medium-term (5.1-12 years) estimate of the potential cost savings when 50% of US adults consume high-MUFA oils. The pessimistic scenario is a short-to medium-term (2.1-5 years) estimate of potential cost savings when 25% of US adults consume high-MUFA oils. The very pessimistic scenario represents the least-case estimate when only 10% of US adults consume the recommended MUFA level daily over a short term (first 2 years). Values (95%CI) are annual type 2 diabetes-related direct and indirect economic savings from the consumption of 17% energy from high-MUFA oil per day. The universal scenario represents the best-case assumption of potential savings if all US adults !18 years were to consume high-MUFA oils over a long term (7.5 to >10 years). The optimistic scenario is a medium-term (5-7.5 years) estimate of the potential cost savings when 50% of US adults consume high-MUFA oils. The pessimistic scenario is a short-to medium-term (2.5-5 years) estimate of potential cost savings when 25% of US adults consume high-MUFA oils. The very pessimistic scenario represents the least-case estimate when only 10% of US adults consume the recommended MUFA level daily over a short term (first 2.5 years). b Includes oral medications and noninsulin injectable antidiabetic agents. Includes, but not limited to, eyewear, orthopedic items, hearing devices, prostheses, bathroom aids, medical equipment, and disposable supplies.
savings were estimated at USD $33.5 billion (95%CI, $19.6-$46.6 billion) for CHD costs and USD $7.4 billion (95%CI, À$9.7 to $24.4 billion) for T2D costs. The optimistic scenario, assuming a 50% success rate and a medium-term benefit, predicted savings of USD $15.5 billion (95%CI, $9.1-$21.6 billion) in CHD costs and USD $3.2 billion (95%CI, À$4.2 to $10.6 billion) in T2D costs annually. The pessimistic scenario, which assumed a 25% success rate and a short-to medium-term benefit, showed savings of USD $6.8 billion (95%CI, $4.0-$9.5 billion) in CHD costs and USD $1.2 billion (95%CI, À$1.6 to $4.1 billion) in T2D costs annually. Lastly, a least-case scenario that assumed a 10% success rate and a benefit over the short term suggested a potential total annual savings of USD $0.9 billion (95%CI, $0.5-$1.2 billion) for CHD and USD $0.4 billion (95%CI, À$0.5 to $1.3 billion) for T2D costs.
DISCUSSION
This research describes the potential savings in healthcare and societal costs if the United States switched from lower to higher MUFA intakes. Primarily, the findings suggest that, if 10% to 100% of the US adult population adopted a level of 17% of their daily energy as MUFAs by replacing oils rich in SFAs, TFAs, and PUFAs in their diets, the subsequent reductions in the risk of CHD and T2D combined could potentially save between USD $1.3 billion (95%CI, $0.0-$2.5 billion) and USD $40.9 billion (95%CI, $9.9-$71.0 billion) in healthcare and lost productivity/mortality costs, per year, over up to 2.5 years and beyond 12 years, respectively. With the same level of MUFA consumption among 25% and 50% of US adults, the combined savings in CHD and T2D costs could reach USD $8.0 billion (95%CI, $2.4-$13.6 billion) and USD $18.7 billion (95%CI, $4.9-$32.2 billion) annually over 5 years and up to 12 years, respectively. The substantial cost of healthcare is a global concern that calls for actions at both the individual and societal levels worldwide. 1 Protective impacts of higher MUFA intakes on established risk factors for specific diseases, including CHD and T2D, two of the global leading causes of mortality and substantial societal burden, are acknowledged. 88, 89 It is thus reasonable that reductions in the incidence of these diseases following increased adherence to MUFA-based diets could result in savings related to the escalating costs of these two diet-related epidemics. The authors are aware of no studies that have examined such associations, however, except for the recent economic model of the estimated savings on heart disease-associated medical care and job absenteeism costs resulting from substituting MUFA for saturated fat, based on data from the 2000-2010 Medical Expenditure Panel Survey. 90 The scenarios presented in the present model complement previous findings 90 and represent possible sequential CHD and T2D risk reductions and cost savings as increasing proportions of the population elevate their MUFA intake. In theory, in the first couple of years, a lower percentage of people would be expected to replace their regular dietary fats with MUFA-rich oils, hence the full benefits of such dietary change would not be realized during this period, and the cost savings related to disease would be modest. As time progresses, awareness of the advantages of a high MUFA intake, combined with the increased marketing and popularity of MUFArich oil and the decreased cost of oil production resulting from higher sale volumes, would all be expected to lead to a greater percentage of consumers adopting this dietary behavior over the medium term (up to 5 years and a little beyond), thus leading to proportionally greater healthcare cost savings. By year 10 and beyond, perhaps between half and all of the population would achieve the target of 17% energy intake from a MUFAbased diet, resulting in the greatest annual savings in costs associated with the diseases of interest. It should be noted, however, that although the model in its present structure is meant to reflect increasing rates of adoption over a theoretical time scale in each scenario, it stops short of exploring the time value of money by discounting the future stream of cost savings to a present value. The progression through these scenarios, therefore, may not necessarily reflect the passage of time. Future conventional cost-benefit analyses are warranted to address such costs and benefits related to a dietary behavior over time.
This study focused mainly on substituting MUFA intake for all categories of dietary fat (SFA, TFA, and PUFA). However, one can speculate that if individuals with particularly higher intakes of SFA and TFA 91 replace only those fat types with MUFA, greater cost savings related to CHD and T2D would accrue (see Tables  S1-S5 in the Supporting Information online). Replacing SFA and TFA with MUFA has become tractable and palatable especially in the past decade with appearance in the marketplace of high MUFA, low SFA oils, including high-oleic canola oil (73% MUFA, 7% SFA), high-oleic safflower oil (84% MUFA, 10% SFA), and high-oleic algae oil (90% MUFA, 4% SFA).
The findings of the present work highlight the importance of promoting MUFA intake in the United States. This is an example of a public health strategy to alleviate the financial pressure within the US healthcare system or to drive public and private healthcare initiatives toward priorities such as education, knowledge translation, and infrastructure. Before this can take place, however, careful assessment of the feasibility for populations to replace their current dietary fats, especially SFAs and TFAs, with the recommended level of MUFA intake is warranted. In this regard, the NHANES 2011-2012 (National Health and Nutrition Examination Survey 2011-2012) 3 reported that the intake of MUFAs for both men and women is 12% of total energy, which is nearly the same as the SFA intake (11%) and almost double that of the PUFA intake (7%).
3 US Department of Agriculture data on "kilocalories contributed from major food groups to the US food supply" show that, in 2010, 22.5% of calories in the food supply were from added fats and oils, including butter (1.1%), margarine (0.8%), shortening (4.2%), lard, beef, and tallow (1.3%), and salad and cooking oils (15.1%). 92 These data suggest that, if people replace at least part of their regular salad and cooking oils (for instance) with a high-MUFA oil and switch to a high-MUFA spread rather than using butter or margarine, the target of 17% energy from MUFAs is realistic and achievable. This scenario also sits within the range of a moderate intake of 15% to 20% dietary energy from MUFAs, as recommended by the Academy of Nutrition and Dietetics, 2 and leaves room for adequate intake levels of other fatty acids, in particular the essential n-6 linoleic acid and n-3 alpha-linolenic acid, for which the recommended daily intakes are in the 2%-4% and 0.5%-0.7% range, respectively. Moreover, with the expansion in the popularity of MUFA-rich oils in the marketplace, 93 food processors have been substituting away from SFAs and TFAs to MUFAs in recent years. Along these lines, the US Food and Drug Administration finalized in June 2015 its determination that partially hydrogenated oils are not "generally recognized as safe" for use in human foods and gave food manufacturers 3 years to remove partially hydrogenated oils from food products. 94 While it is possible that food manufacturers may transition from partially hydrogenated oils to SFA-and/or PUFA-rich oils, a portion of the reformulated food products will also likely utilize MUFA-rich oils as a replacement fat, especially when MUFA-rich oil is perceived as a favorable component of diets and when consumers are generally receptive to it. Additionally, findings from a 2009 Canadian national systematic assessment of grocery and restaurant foods likely to contain TFAs suggest that "manufacturers/restaurants generally take advantage of costs and efforts of reformulation to not only reduce TFA but also increase the content of cis unsaturated fats." 95 As such, it is overall reasonable to assume that Americans would not have difficulties with incorporating high-oleic oils in their daily diets or substituting about half of their dietary energy from fat intake with MUFA-rich oils and fats that are now available in the marketplace. Still, consumer behavior research is warranted to address the economic perspective of such a dietary change.
In addition to health quality, taste, and culture, price is one of the key factors that determine the consumer's food choices at home and in the marketplace. 96 While the focus of this economic work is on healthcare cost savings, potential non-healthcare costs associated with higher MUFA intake are worth noting. Such costs may stem from the food processing and retailing sector, for instance through product reformulation, or a possible increase in consumer expenditure on MUFA-rich oils, which could partially offset the cost savings estimates presented here. Although not all oils high in MUFAs are more expensive than other dietary oils in the marketplace, more studies are needed to explore this topic. Furthermore, to increase consumption of MUFAs among populations, collaborative efforts by stakeholders such as the food industry and dietitians, accompanied by public health policies and educational messages to promote optimal and balanced intakes of healthy dietary fatty acid profiles, are important. Such efforts would also be expected to require some funding allocated to governmental programs and food industry marketing campaigns to bring further awareness to the general public. Again, however, such costs would fall outside of the US healthcare system.
On the other hand, the present analysis can be perceived as conservative by design, partly because some healthcare savings beyond those related to CHD or T2D may accrue following increased intakes of MUFA-rich oils. Furthermore, while the analysis utilized CHD costs in the United States by taking into account the effects of changes in dietary fatty acid intakes on atherosclerosis (thus CHD), risks of cerebrovascular disease, renal disease, and peripheral artery disease may also be improved by increased intakes of MUFAs. Given the inherently higher costs of cardiovascular disease compared with CHD, the economic benefits of higher MUFA intakes are potentially greater than what was estimated in the present analysis. It is also worth noting that the percent reduction in serum TC (rather than a higher percent reduction in LDL-C) was utilized in the calculations merely on the basis that, to the best of knowledge, available studies with LDL-C either do not report percent reduction (instead reporting values in mmol/L) or do not link such reduction in LDL-C concentrations with CHD in particular, but rather to cardiovascular disease in general. The costs of diabetes utilized in this analysis, however, reflect "continued growth in prevalence of diabetes and its complications; changing healthcare practices, technology, and cost of treatment; and changing economic conditions." 83 In any case, future cost-benefit or cost-effectiveness analyses are anticipated to shed further light on the total lifetime costs and benefits associated with higher MUFA intakes.
This work is, to the best of knowledge, the first to examine the potential savings in healthcare and societal costs attributed to lower rates of CHD and T2D subsequent to attainable levels of MUFA intakes in the United States. Application of the model's 4 steps and analysis parameters were made possible through most recent literature and comprehensive databases of monetary figures, with adjustment for current values. Some limitations exist, however.
While the influence of higher MUFA intakes on cholesterol concentrations as a biomarker of CHD was cited in several reports, only a few studies from the present review of the literature examined the impact of MUFA intake on HbA1c concentrations as a biomarker of T2D risk. The cost savings for T2D that are projected in this work should thus be interpreted with caution, while further research into the potential diabetes-related cost benefits following higher MUFA consumption is warranted. Other markers, including circulating glucose and insulin concentrations, as well as body weight and percent fat as risk factors for obesity, were also examined in the present review, although economic analyses were not performed on them. This was because of a lack of evidence directly associating reductions in glucose and insulin concentrations with percent reductions in the incidence of T2D and the fact that the present review identified slightly higher body weights (þ0.06%) with each 1% of total energy intake from MUFA, without a corresponding increase in body fat. Assessment of heterogeneity, risk of publication bias, or quality of the included studies, together with sensitivity analyses comparing short-vs long-term clinical trials, would have strengthened the conclusion on the findings of the present work. Other limitations pertain to the imperfect research on both the consumer perception of MUFA-rich oils in the United States and the average daily intake of MUFAs from fats and oils in particular. In addition, it is logical that isolating the effects of MUFAs from other elements of lifestyle is a challenging case, especially in an era of a "toxic food environment." 97 
CONCLUSION
This review of the clinical literature and the cost savings evaluation sheds original light on the economic benefits that could accompany improvements in established biomarkers of heart health and glycemic control with attainable levels of dietary MUFA consumption among the US adult population. Given the constantly increasing burden of healthcare costs and the increasing availability of MUFA-rich oils and food products in recent years, the present findings are expected to have practical implications for consumers, health professionals, and decision-making authorities in the United States and worldwide.
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